TRI-MILI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-MILI (TRI-MILI).
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
| Metabolism | Norethindrone is metabolized via reduction and sulfate/glucuronide conjugation; CYP3A4 is involved. Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation with sulfate and glucuronide. |
| Excretion | Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized. |
| Half-life | Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment. |
| Protein binding | Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 70-90% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; clinical effects persist for dosing interval. |
| Molecular Weight | 425.5 |
| Action Class | Combined Oral Contraceptive (COC); Estrogen-Progestin Combination |
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if CrCl <30 mL/min. For CrCl 30-50 mL/min: reduce dose to maximum 1 tablet daily; monitor serum potassium frequently. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: initiate at half the usual dose and titrate cautiously. Child-Pugh Class C: contraindicated. |
| Pediatric use | Safety and efficacy not established in children <18 years; use not recommended. |
| Geriatric use | Start at lowest possible dose (e.g., 0.5 tablet daily) due to increased risk of electrolyte imbalances and hypotension; monitor renal function and serum potassium closely. |
| 1st trimester | Avoid due to potential teratogenic effects. Studies in animals have shown fetal abnormalities. |
| 2nd trimester | Use only if clearly needed. May cause fetal harm; consider risk-benefit. |
| 3rd trimester | Avoid during third trimester as it may cause adverse effects in the neonate. |
Clinical note
Comprehensive clinical and safety monograph for TRI-MILI (TRI-MILI).
| Placental transfer | Crosses placenta; detected in fetal plasma at approximately 50-80% of maternal levels. |
| Breastfeeding | Excreted in breast milk in low concentrations. Use with caution; monitor infant for potential effects. |
| Lactation Rating |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women >35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular menstrual bleeding, Mood changes, Acne |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Worsening of migraine headaches, Optic neuritis or retinal thrombosis |
Hypersensitivity to tri-mili or any componentPregnancy (unless clearly needed)Severe renal impairment
| Precautions | Thrombotic disorders (e.g., DVT, PE, MI, stroke): discontinue if symptoms occur, Hepatic disease: discontinue if jaundice or impaired liver function, Hypertension: monitor blood pressure, discontinue if uncontrolled, Gallbladder disease: increased risk of cholecystitis and cholelithiasis, Carbohydrate metabolism: monitor glucose in diabetic patients, Headache: evaluate for migraine or cerebrovascular ischemia, Uterine bleeding: rule out pregnancy or malignancy, Depression: discontinue if severe or recurrent, Ocular effects: discontinue if papilledema or retinal vascular lesions, Drug interactions: reduced contraceptive efficacy with CYP3A4 inducers (e.g., rifampin, anticonvulsants, St. John's wort) |
Loading safety data…
| L3 - Moderately Safe |
| Teratogenic Risk | Tri-Mili (ethinyl estradiol/norethindrone) is contraindicated in pregnancy. First trimester exposure: meta-analyses show no major increased risk of birth defects, but case-control studies suggest a possible small increased risk of cardiovascular malformations and hypospadias. Second and third trimester exposure: androgenic effects on female fetuses (labial fusion, clitoromegaly) and possible estrogenic effects on male fetuses (penile hypoplasia). Use in pregnancy is not indicated; if exposure occurs, evaluate for potential anomalies. |
| Fetal Monitoring | Monitor for signs of thromboembolism (leg pain/swelling, chest pain, dyspnea), hypertension (blood pressure checks at each visit), and hepatic function (ALT, AST) if symptoms occur. In pregnancy rule out via urine beta-hCG before initiating. No specific fetal monitoring required if used inadvertently; ultrasound to assess fetal anatomy if exposure occurs. |
| Fertility Effects | Tri-Mili suppresses ovulation via inhibition of gonadotropins; fertility returns to baseline within 1-3 months after discontinuation. No evidence of long-term impairment of fertility. Use does not cause infertility. |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to ensure stable absorption. |
| Clinical Pearls | TRI-MILI is a combination oral contraceptive containing ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35 or with hypertension. Counsel patients to take at the same time daily; missed doses increase breakthrough bleeding and pregnancy risk. Consider drug interactions with rifampin, carbamazepine, and certain antibiotics. |
| Patient Advice | Take one pill at the same time every day, even if you do not have sex often. · If you miss a pill, follow the package instructions or consult your healthcare provider. · Do not smoke while taking this medication; smoking increases your risk of blood clots. · Contact your doctor if you experience leg pain, shortness of breath, chest pain, or severe headaches. · Use backup contraception if you vomit or have severe diarrhea within 3-4 hours after taking a pill. |